DESTINY-Lung02 trial

CHMP opinion, EMA approval, Daiichi Sankyo, Enhertu, Non-Small Cell Lung Cancer, HER2 Mutant NSCLC, DESTINY-Lung02 trial
Latest News Approvals Pharma

Enhertu, a Breakthrough Therapy for HER2 Mutant NSCLC, Gets EU Nod

Anika Sharma

Enhertu (trastuzumab deruxtecan) has received a positive recommendation for approval in the European Union (EU) as a standalone treatment for ...

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

© 2025 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us